Compare AMCX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCX | NERV |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.2M | 269.6M |
| IPO Year | 2011 | 2014 |
| Metric | AMCX | NERV |
|---|---|---|
| Price | $6.74 | $7.70 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $7.00 | $7.00 |
| AVG Volume (30 Days) | ★ 432.4K | 194.4K |
| Earning Date | 05-08-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.55 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $2,311,801,000.00 | $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.41 | $1.15 |
| 52 Week High | $10.28 | $12.46 |
| Indicator | AMCX | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 64.59 |
| Support Level | $5.69 | $5.34 |
| Resistance Level | $8.24 | $12.46 |
| Average True Range (ATR) | 0.36 | 0.71 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 3.03 | 70.37 |
AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.